How safe and effective is radiosurgical treatment for patients with 10 or more BM?

Clicks: 17
ID: 326999
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #93 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background We evaluated the outcome of radiosurgically treated patients with ≥10 brain metastases (BM), compared to patients <10 BM. Methods Patients, who underwent at least one Gamma Knife radiosurgical (GKRS) treatment for at least one BM without previous CNS treatments, were retrospectively divided into two groups: 1) <10 or 2) ≥10 BM. Results At GKRS1, 1293 patients had <10 BM and 126 patients had ≥10 BM. The estimated median survival after GKRS1 was significantly longer in patients with <10 BM (9.9 months), compared to patients with ≥10 BM at GKRS1 (5.3 months; p < 0.001). Age >65 years (p < 0.001), male sex (p = 0.001), Karnofsky Performance Status Scale <80 (p < 0.001), presence of extracranial metastases (p = 0.008), presence of neurological symptoms (p = 0.019), a cumulative BM volume of all BM treated at GKRS1 ≥10 cm3 (p = 0.017), no concomitant immunotherapy or targeted therapy at GKRS1 (p < 0.001), and the number of ≥ 10 BM at GKRS1 (p < 0.001), were identified as independent prognostic factors for an increased risk of death. In patients with ≥10 BM, poor clinical condition, a cumulative BM volume of all BM treated ≥25 cm3, and no concomitant immunotherapy or targeted therapy at GKRS1 were identified as significant independent prognostic factors. The occurrence of post-radiosurgical complications and local tumor control did not differ between the groups. Conclusions In addition to BM count, multiple factors may influence survival and should be considered during the pre-radiosurgery assessment. GKRS represents a safe and effective first-line treatment method even for patients with ≥10 BM, particularly in the era of modern systemic therapies.
Reference Key
openalex_W7204877198 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anna Cho, Thore Jankowski, Yiru Chen, Lukas Kohlmaier, Brigitte Gatterbauer, Philip Lederer, Lukas Haider, D I Sonja Tögl, Karl Rössler, Christian Dorfer, Philippe Dodier, Christoph Höller, Rupert Bartsch, Maximilian J. Hochmair, Josa M. Frischer
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag229
URL
https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdag229/70896173/vdag229.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.